查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1957517

2026年全球核医放射性同位素市场报告

Nuclear Medicine Radioisotopes Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，核医放射性同位素市场规模显着成长。预计该市场将从2025年的88.5亿美元成长到2026年的95.8亿美元，复合年增长率（CAGR）为8.2%。过去几年的成长主要归功于Technetium-99m在诊断影像中的广泛应用、核医学心臟影像的日益普及、癌症和甲状腺疾病发病率的上升、医院核医学科室的扩建以及放射性同位素疗法的早期临床成功。

预计未来几年，核医放射性同位素市场规模将强劲成长。到2030年，该市场规模预计将达到127.5亿美元，复合年增长率（CAGR）为7.4%。预测期内的成长要素包括：对个人化癌症治疗的需求不断增长、镏-177和锕-225疗法的应用日益广泛、PET成像基础设施的扩建、对迴旋加速器和反应器设施投资的增加，以及新兴国家核医学应用的进步。预测期内的主要趋势包括：肿瘤治疗中诊疗一体化治疗诊断学的日益普及、对PET和SPECT成像技术的需求不断增长、靶向α射线和β核子反应炉发射体的使用日益增多、核医学在心臟病学和神经病学领域的应用不断扩展，以及对国内放射性同位素生产的日益重视。

未来几年，心血管疾病发生率的上升预计将推动核医放射性同位素市场的扩张。心血管疾病是指影响心臟和血管的多种疾病。心血管疾病病例的增加与久坐的生活方式、不良的饮食习惯、肥胖率的上升以及人口老化密切相关。核医放射性同位素能够提供有关心臟功能、血流和组织活力的详细信息，对于心血管疾病的诊断、评估和治疗至关重要，也是准确诊断和有效治疗方案製定的关键。例如，根据美国心臟协会（美国非营利组织）于2024年1月发布的数据，预计2024年心血管疾病的年龄调整死亡率将达到每10万人233.3例，比2023年的224.4例增加4.0%。因此，心血管疾病盛行率的上升正在推动核医学放射性同位素市场的成长。

核医放射性同位素市场的主要企业正致力于开发先进解决方案，例如新一代诊疗治疗诊断学药物，以提升精准成像和标靶治疗。新一代诊疗治疗诊断学放射性药物是高度专业化的放射性药物，能够精准靶向体内特定细胞，从而实现疾病的检测和精准治疗。例如，2025年11月，美国研究型大学加州大学（University of California）成立了完全独立的“核医学与治疗诊断学系”，不再将核子医学作为放射科的一部分。该系旨在加速先进成像技术和标靶放射性药物疗法的应用，并加强研究、教育和临床项目，以推进精准医学发展，促进诊疗治疗诊断学治疗领域的创新。

目录

第一章执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球核医放射性同位素市场：吸引力评分及分析
  • 成长潜力分析、竞争评估、策略适宜性评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 清单：主要原料、资源和供应商
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章：全球市场趋势与策略

  • 关键科技与未来趋势
    • 生物技术、基因组学和精准医疗
    • 人工智慧（AI）和自主人工智慧
    • 工业4.0和智慧製造
    • 数位化、云端运算、巨量资料、网路安全
    • 物联网、智慧基础设施、互联生态系统
  • 主要趋势
    • 肿瘤治疗中诊疗治疗诊断学的广泛应用
    • 对PET和SPECT成像程序的需求增加
    • 扩大标靶α射线和β射线发射放射性核素的使用
    • 核子医学在心臟病学和神经病学领域的拓展
    • 加强对国内放射性同位素生产的重视

第五章 终端用户产业市场分析

  • 医院
  • 诊断中心
  • 专科诊所
  • 癌症治疗中心
  • 教育和研究机构

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及 COVID-19 疫情对市场的影响。

第七章：全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球核医放射性同位素市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 核医放射性同位素的全球市场规模、比较与成长率分析。
  • 全球核医放射性同位素市场表现：规模与成长，2020-2025年
  • 全球核医放射性同位素市场预测：规模与成长，2025-2030年，2035年预测

第八章：全球市场总规模（TAM）

第九章 市场细分

  • 按类型
  • Technetium-99m (Tc-99m)、铊-201 (Tl-201)、碘-123 (I-123)、氟-18、铷-82 (Rb-82)、碘-131 (I-131)、镏-177 (镏-2317)、铄Alpharadin等。
  • 透过使用
  • 肿瘤学、心臟病学、甲状腺病学、神经病学及其他应用领域
  • 最终用户
  • 医院、诊断中心、专科诊所、教育和研究机构以及其他最终用户
  • 按类型细分：Technetium-99m (Tc-99m)
  • Technetium-99m 高锝酸钠、Technetium-99m MDP（亚甲基二膦酸）、Technetium-99m HMPAO（六甲基丙烯胺肟）
  • 按类型细分：铊-201 (Tl-201)
  • 氯化铊（Tl-201），用于心臟显像的铊-201
  • 按类型细分：碘-123 (I-123)
  • 碘-123 碘化钠，碘-123 碘氟烷（DatScan）
  • 按类型细分：氟-18
  • FDG（氟代脱氧葡萄糖）F-18，氟化物-18用于骨骼影像诊断
  • 按类型细分：铷-82 (Rb-82)
  • Rb-82（用于PET（正子断层扫描）影像），Rb-82（用于心臟影像）
  • 按类型细分：碘-131 (I-131)
  • 碘-131（碘化钠），碘-131用于治疗甲状腺癌，碘-131用于治疗甲状腺亢进
  • 按类型细分：镏-177 (Lu-177)
  • 镏-177-DOTATATE、镏-177 用于治疗前列腺癌
  • 按类型细分：镭-223 (Ra-223) 和Alpharadin
  • 二氯化镭-223（佐菲戈）， Alpharadin，用于治疗骨转移
  • 按类型细分：其他类型
  • 用于标靶α疗法（TAT）的Ac-225、癌症治疗的Ac-225、镓-68（Ga-68）、铜-64（Cu-64）、钇-90（Y-90）

第十章 区域与国别分析

  • 全球核医放射性同位素市场：依地区划分，历史资料及预测（2020-2025年、2025-2030年、2035年）
  • 全球核医放射性同位素市场：依国家划分，历史资料及预测，2020-2025年、2025-2030年、2035年

第十一章 亚太市场

第十二章：中国市场

第十三章：印度市场

第十四章：日本市场

第十五章：澳洲市场

第十六章：印尼市场

第十七章：韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第20章 西欧市场

第21章英国市场

第22章：德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章：东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第三十章：加拿大市场

第31章：南美市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第三十五章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 核医放射性同位素市场：竞争格局与市场份额，2024年
  • 核子医学放射性同位素市场：公司估值矩阵
  • 核医放射性同位素市场：公司概况
    • Cardinal Health Inc.
    • Bayer AG
    • Siemens Healthineers AG
    • GE HealthCare Technologies
    • BWX Technologies Inc.

第37章 其他大型企业和创新企业

  • Mallinckrodt Pharmaceuticals, Bracco Imaging SpA, Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation（ANSTO）Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., EczacIbasI-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z oo, Radiomedix Inc.

第38章：全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年核医放射性同位素市场：提供新机会的国家
  • 2030年核医放射性同位素市场：新兴细分市场机会
  • 2030年核医放射性同位素市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第41章附录

简介目录
Product Code: PH5MNMRE01_G26Q1

Nuclear medicine radioisotopes are radioactive isotopes used in nuclear medicine to diagnose, treat, and investigate various medical conditions. These isotopes emit radiation that can be detected and imaged with specialized equipment or can provide therapeutic doses of radiation to targeted tissues. Nuclear medicine radioisotopes are essential in modern medical diagnostics and treatments, providing critical information and therapeutic options that improve patient outcomes.

The main types of nuclear medicine radioisotopes include technetium-99m (Tc-99m), thallium-201 (Tl-201), iodine (I-123), fluorine-18, rubidium-82 (Rb-82), iodine-131 (I-131), lutetium-177 (Lu-177), radium-223 (Ra-223) and alpharadin, actinium-225 (Ac-225), among others. Technetium-99m (Tc-99m) is a radioactive isotope widely utilized in nuclear medicine imaging procedures for the diagnosis of various medical conditions. Its uses cover areas such as oncology, cardiology, thyroid, neurology, and more, serving end users including hospitals, diagnostic centers, specialty clinics, education and research institutes, and others.

Tariffs have impacted the nuclear medicine radioisotopes market by increasing costs associated with importing radioisotopes, enriched materials, cyclotron components, and shielding equipment. These effects are most pronounced in regions dependent on cross-border isotope supply chains, including North America and parts of Europe. Supply disruptions and higher logistics costs have affected diagnostic and therapeutic segments, particularly short half-life isotopes. However, tariffs have also encouraged domestic isotope production, regional cyclotron investments, and supply chain localization, supporting long-term market resilience.

The nuclear medicine radioisotopes market research report is one of a series of new reports from The Business Research Company that provides nuclear medicine radioisotopes market statistics, including nuclear medicine radioisotopes industry global market size, regional shares, competitors with a nuclear medicine radioisotopes market share, detailed nuclear medicine radioisotopes market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine radioisotopes industry. This nuclear medicine radioisotopes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nuclear medicine radioisotopes market size has grown strongly in recent years. It will grow from $8.85 billion in 2025 to $9.58 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to widespread use of technetium-99m in diagnostic imaging, growing adoption of nuclear cardiology procedures, increasing prevalence of cancer and thyroid disorders, expansion of hospital-based nuclear medicine departments, early clinical success of radioisotope-based therapies.

The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $12.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising demand for personalized cancer treatment, increasing use of lutetium-177 and actinium-225 therapies, expansion of PET imaging infrastructure, growing investments in cyclotron and reactor facilities, rising adoption of nuclear medicine in emerging economies. Major trends in the forecast period include rising adoption of theranostics in oncology care, growing demand for PET and SPECT imaging procedures, increased use of targeted alpha and beta emitters, expansion of nuclear medicine in cardiology and neurology, strengthening focus on domestic radioisotope production.

The rising incidence of cardiovascular diseases is expected to drive the expansion of the nuclear medicine radioisotope market in the coming years. Cardiovascular diseases include a variety of conditions that affect the heart and blood vessels. The increase in cardiovascular disease cases is linked to sedentary lifestyles, poor dietary habits, higher obesity rates, and aging populations. Nuclear medicine radioisotopes are essential for diagnosing, evaluating, and managing cardiovascular diseases by offering detailed information on cardiac function, perfusion, and tissue viability, which are vital for accurate diagnosis and effective treatment planning. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. As a result, the increasing prevalence of cardiovascular diseases is driving the growth of the nuclear medicine radioisotope market.

Major companies in the nuclear medicine radioisotopes market are focusing on developing advanced solutions such as next-generation theranostic radiopharmaceuticals to enhance precision imaging and targeted therapies. Next-generation theranostic radiopharmaceuticals are highly specialized radioactive agents designed to both detect and accurately treat diseases by precisely targeting specific cells within the body. For instance, in November 2025, the University of California, a US-based research university, created a completely independent Department of Nuclear Medicine & Theranostics, rather than maintaining nuclear medicine as part of a broader radiology division. This newly established department aims to accelerate the use of advanced imaging and targeted radiopharmaceutical therapies. It also strengthens research, education, and clinical programs to advance precision medicine and encourage innovations in theranostic treatments.

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired ARTMS for an undisclosed amount. Through this acquisition, Telix Pharmaceuticals aimed to strengthen its nuclear medicine capabilities, optimize production processes, and broaden its range of diagnostic and therapeutic radiopharmaceuticals. ARTMS, headquartered in Canada, provides advanced radioisotope technology and operates in the field of nuclear medicine radioisotopes.

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., EczacIbasI-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuclear medicine radioisotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nuclear medicine radioisotopes market consists of sales of yttrium-90, indium-111, carbon-11, samarium-153, and strontium-89. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Medicine Radioisotopes Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses nuclear medicine radioisotopes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nuclear medicine radioisotopes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nuclear medicine radioisotopes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Technetium-99m (Tc-99m); Thallium-201 (Tl-201); Iodine (I-123); Fluorine-18; Rubidium-82 (Rb-82); Iodine-131 (I-131); Lutetium-177 (Lu-177); Radium-223 (Ra-223) And Alpharadin; Other Types
  • 2) By Application: Oncology; Cardiology; Thyroid; Neurology; Other Applications
  • 3) By End-User: Hospitals; Diagnostic Centers; Specialty Clinics; Education And Research Institutes; Other End-Users
  • Subsegments:
  • 1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m; Tc-99m MDP (Methylene Diphosphonate); Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
  • 2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201; Thallium-201 for Cardiac Imaging
  • 3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide; Iodine-123 Ioflupane (DaTscan)
  • 4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18; Fluoride-18 For Bone Imaging
  • 5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging; Rb-82 For Cardiac Imaging
  • 6) By Iodine-131 (I-131): I-131 Sodium Iodide; I-131 For Thyroid Cancer Treatment; I-131 For Hyperthyroidism Treatment
  • 7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE; Lu-177 For Prostate Cancer Treatment
  • 8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo); Alpharadin For Bone Metastasis Treatment
  • 9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT); Ac-225 For Cancer Treatment; Gallium-68 (Ga-68); Copper-64 (Cu-64); Yttrium-90 (Y-90)
  • 10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT); Ac-225 For Cancer Treatment; Gallium-68 (Ga-68); Copper-64 (Cu-64); Yttrium-90 (Y-90)
  • Companies Mentioned: Cardinal Health Inc.; Bayer AG; Siemens Healthineers AG; GE HealthCare Technologies; BWX Technologies Inc.; Mallinckrodt Pharmaceuticals; Bracco Imaging S.p.A.; Lantheus Holdings Inc.; Curium Pharma; Australian Nuclear Science and Technology Organisation (ANSTO) Health; Eckert & Ziegler Strahlen; NorthStar Medical Radioisotopes; NTP Radioisotopes; Shine Medical Technologies Inc.; Jubilant DraxImage Inc.; Isotopia Molecular Imaging Ltd.; EczacIbasI-Monrol Nuclear Products; International Isotopes Inc.; Polatom Sp. z o.o.; Radiomedix Inc.; Positron Corporation
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Nuclear Medicine Radioisotopes Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Nuclear Medicine Radioisotopes Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Nuclear Medicine Radioisotopes Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Nuclear Medicine Radioisotopes Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Rising Adoption Of Theranostics In Oncology Care
    • 4.2.2 Growing Demand For Pet And Spect Imaging Procedures
    • 4.2.3 Increased Use Of Targeted Alpha And Beta Emitters
    • 4.2.4 Expansion Of Nuclear Medicine In Cardiology And Neurology
    • 4.2.5 Strengthening Focus On Domestic Radioisotope Production

5. Nuclear Medicine Radioisotopes Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Diagnostic Centers
  • 5.3 Specialty Clinics
  • 5.4 Cancer Treatment Centers
  • 5.5 Education And Research Institutes

6. Nuclear Medicine Radioisotopes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Nuclear Medicine Radioisotopes Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Nuclear Medicine Radioisotopes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Nuclear Medicine Radioisotopes Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Nuclear Medicine Radioisotopes Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Nuclear Medicine Radioisotopes Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Nuclear Medicine Radioisotopes Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Nuclear Medicine Radioisotopes Market Segmentation

  • 9.1. Global Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types
  • 9.2. Global Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oncology, Cardiology, Thyroid, Neurology, Other Applications
  • 9.3. Global Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users
  • 9.4. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Technetium-99m (Tc-99m), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
  • 9.5. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Thallium-201 (Tl-201), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Thallous Chloride Tl-201, Thallium-201 For Cardiac Imaging
  • 9.6. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Iodine-123 (I-123), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)
  • 9.7. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Fluorine-18, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging
  • 9.8. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Rubidium-82 (Rb-82), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging
  • 9.9. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Iodine-131 (I-131), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment
  • 9.10. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Lutetium-177 (Lu-177), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment
  • 9.11. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Radium-223 (Ra-223) And Alpharadin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment
  • 9.12. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

10. Nuclear Medicine Radioisotopes Market Regional And Country Analysis

  • 10.1. Global Nuclear Medicine Radioisotopes Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Nuclear Medicine Radioisotopes Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Nuclear Medicine Radioisotopes Market

  • 11.1. Asia-Pacific Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Nuclear Medicine Radioisotopes Market

  • 12.1. China Nuclear Medicine Radioisotopes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Nuclear Medicine Radioisotopes Market

  • 13.1. India Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Nuclear Medicine Radioisotopes Market

  • 14.1. Japan Nuclear Medicine Radioisotopes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Nuclear Medicine Radioisotopes Market

  • 15.1. Australia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Nuclear Medicine Radioisotopes Market

  • 16.1. Indonesia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Nuclear Medicine Radioisotopes Market

  • 17.1. South Korea Nuclear Medicine Radioisotopes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Nuclear Medicine Radioisotopes Market

  • 18.1. Taiwan Nuclear Medicine Radioisotopes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Nuclear Medicine Radioisotopes Market

  • 19.1. South East Asia Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Nuclear Medicine Radioisotopes Market

  • 20.1. Western Europe Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Nuclear Medicine Radioisotopes Market

  • 21.1. UK Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Nuclear Medicine Radioisotopes Market

  • 22.1. Germany Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Nuclear Medicine Radioisotopes Market

  • 23.1. France Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Nuclear Medicine Radioisotopes Market

  • 24.1. Italy Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Nuclear Medicine Radioisotopes Market

  • 25.1. Spain Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Nuclear Medicine Radioisotopes Market

  • 26.1. Eastern Europe Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Nuclear Medicine Radioisotopes Market

  • 27.1. Russia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Nuclear Medicine Radioisotopes Market

  • 28.1. North America Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Nuclear Medicine Radioisotopes Market

  • 29.1. USA Nuclear Medicine Radioisotopes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Nuclear Medicine Radioisotopes Market

  • 30.1. Canada Nuclear Medicine Radioisotopes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Nuclear Medicine Radioisotopes Market

  • 31.1. South America Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Nuclear Medicine Radioisotopes Market

  • 32.1. Brazil Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Nuclear Medicine Radioisotopes Market

  • 33.1. Middle East Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Nuclear Medicine Radioisotopes Market

  • 34.1. Africa Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Nuclear Medicine Radioisotopes Market Regulatory and Investment Landscape

36. Nuclear Medicine Radioisotopes Market Competitive Landscape And Company Profiles

  • 36.1. Nuclear Medicine Radioisotopes Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Nuclear Medicine Radioisotopes Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Nuclear Medicine Radioisotopes Market Company Profiles
    • 36.3.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. GE HealthCare Technologies Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. BWX Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Nuclear Medicine Radioisotopes Market Other Major And Innovative Companies

  • Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., EczacIbasI-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc.

38. Global Nuclear Medicine Radioisotopes Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Nuclear Medicine Radioisotopes Market

40. Nuclear Medicine Radioisotopes Market High Potential Countries, Segments and Strategies

  • 40.1 Nuclear Medicine Radioisotopes Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Nuclear Medicine Radioisotopes Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Nuclear Medicine Radioisotopes Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer